Heather Preston
Direttore/Membro del Consiglio presso OXFORD NANOPORE TECHNOLOGIES PLC
Patrimonio netto: 68 582 $ in data 30/06/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Manoussos Perros | M | 56 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 anni |
| Mike Gutch | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 anni |
| Nicholas G. Galakatos | M | 66 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 anni |
| Peter Bisgaard | M | 50 |
Pivotal Bioventure Partners Investment Advisor LLC
 Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 13 anni |
| Andrew J. Staples | M | 54 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 anni |
| James Topper | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 anni |
| David Hastings | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 6 anni |
| Timothy Cowper | M | - | 12 anni | |
| David Meek | M | 59 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 anni |
| Heather Behanna | M | 49 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 anni |
| Stuart Paynter | M | 52 | 7 anni | |
| Mark W. Surber | M | - |
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 13 anni |
| Robert Hopfner | M | 51 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 7 anni |
| Yair Alster | M | - |
Azura Ophthalmics Pty Ltd.
 Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | 44 anni |
| James WIllcocks | M | - | 19 anni | |
| Natalie Walter | F | 50 | 5 anni | |
| Gordon Sanghera | M | - | 19 anni | |
| John Schoellerman | M | - | 5 anni | |
| Kyle Dow | M | - |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | - |
| Matthew Treagus | M | - | 3 anni | |
| David Malek | M | 47 |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | - |
| Guy Asher Harmelin | M | 45 | 4 anni | |
| David Altarac | M | 63 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 anni |
| Lisa Podos | F | - |
Fine Arts Museums of San Francisco
 Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Namrata Patel | F | - | 2 anni | |
| Ruben Tommasi | M | 58 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 anni |
| John Mueller | M | 64 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 anni |
| Marc Gleeson | M | - |
Azura Ophthalmics Pty Ltd.
Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | - |
| Hannah Coote | F | - | 4 anni | |
| Sam Harman | M | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 5 anni |
| Jack Strudley | M | - |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 8 anni |
| Vincent Cheung | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 7 anni |
| Ming Cheah | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 4 anni |
| Rhodri Davies | M | - | 13 anni | |
| Leone Patterson | F | 61 | 1 anni | |
| Nicholas Keher | M | 42 | - | |
| Alfred S. Wilsey | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Frank Mathias | M | 62 | 1 anni | |
| Jonathan Leff | M | 66 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 7 anni |
| Adrian Hennah | M | 66 | 3 anni | |
| Frederic Roch Doliveux | M | 68 | 4 anni | |
| Christopher Michael Chambers | M | 63 |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | - |
| Mischa Travers | M | - |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | 2 anni |
| Stuart Henderson | M | 66 | 8 anni | |
| Dame Davies | M | 73 | 3 anni | |
| Carl Pascarella | M | 81 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Jack Calhoun | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Thomas Campbell | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Zoe McDougall | F | - | 16 anni | |
| Tiba Aynechi | M | 48 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 12 anni |
| Kyriacos Mitrophanous | M | - | 27 anni | |
| Lyn Baranowski | F | - |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 2 anni |
| Polly Elvin | F | - |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | 4 anni |
| Clive Brown | M | - | 16 anni | |
| Yasunobu Kyogoku | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| John Milton | M | - | - | |
| Sara Agee Le | M | - | 3 anni | |
| Dmitri Bobilev | M | - | 2 anni | |
| Kristen Stoops | F | - | - | |
| George Marcus | M | 82 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Jim Branch | M | - | 13 anni | |
| David Wadhwani | M | 52 |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Christopher Leamon | M | 57 | 3 anni | |
| Jordan J. Herman | M | - | 3 anni | |
| John O'Higgins | M | 59 | 5 anni | |
| Lucy Young Hamilton | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Tracy Burris | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Lisa Zanze | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Lisa Sardegna | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Jason Moment | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Diane B. Wilsey | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| David Fraze | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Marc P. Cruciger | M | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Janet Barnes | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
| Duncan Tatton-Brown | M | 59 | 2 anni | |
| Cynthia Fry Gunn | F | - |
Fine Arts Museums of San Francisco
Fine Arts Museums of San Francisco Other Consumer ServicesConsumer Services Fine Arts Museums of San Francisco owns and operates museums. Its collections include European painting, sculpture, and decorative arts. The company is headquartered in San Francisco. CA. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Mark Litton | M | 56 | 14 anni | |
| Randall Schatzman | M | 69 | 14 anni | |
| Eric Elenko | M | 51 | 10 anni | |
| Alan Montgomery | M | 70 |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | 12 anni |
| Chau Khuong | M | 48 | 8 anni | |
| Christopher Coughlin | M | 71 | 4 anni | |
| Arthur Tzianabos | M | 60 | 4 anni | |
| Ronald Cooper | M | 61 | - | |
| Eric Loumeau | M | 61 | 3 anni | |
| Kevin Chow | M | 54 | 7 anni | |
| Paul Cleveland | M | 67 | - | |
| Jeremy Charles Green | M | 49 | - | |
| David A. Weber | M | 64 | 13 anni | |
| Robert Azelby | M | 56 | 1 anni | |
| Julie Burgess | F | - | 7 anni | |
| Kristina Torfgård | M | 61 | 2 anni | |
| Atul Pande | M | 69 | 5 anni | |
| Iain Robert McGill | M | 51 | 7 anni | |
| Edmund Harrigan | M | 71 | 9 anni | |
| Johan Rutger Christenson | M | 65 | 6 anni | |
| James Breitmeyer | M | 70 | 5 anni | |
| Vickie Capps | F | 62 | 9 anni | |
| Roger Jeffs | M | 62 | 5 anni | |
| Carla da Luz Boren | F | - | 6 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 64 | 64.00% |
| Regno Unito | 31 | 31.00% |
| Canada | 5 | 5.00% |
| Israele | 2 | 2.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Heather Preston
- Contatti personali
